September 6, 2024
Sponsored by SmartLabs
Modern science requires a modern lab. With the emergence of novel therapies, specifically personalized therapies, building a laboratory that can support this research is more crucial than ever. Cell and gene therapies (CGT) have seen significant promise in recent years and the market does not appear to be slowing down anytime soon. However, developing and manufacturing these novel therapies comes with unique challenges. Unlike traditional drugs that are produced in large quantities for global distribution, personalized CGTs require smaller, targeted production runs.
These new requirements demand more adaptable lab environments that can accommodate unique and individualized batch production. Traditional laboratories, designed for higher volumes and fewer drug types, are less suited to the scale-out needs of personalized therapies.
SmartLabs addresses these challenges with a next-generation laboratory platform that integrates drug discovery, development, and GMP manufacturing under one roof. This co-located model allows for efficient use of resources and reduces the need for significant investment in non-scientific services by providing a full spectrum of support offerings. By incorporating these support services into their model, SmartLabs enables clients to focus on developing their process rather than non-research related tasks.
SmartLabs’ facilities are designed to be customizable and flexible, supporting your science at any stage, size and modality. These spaces are built to adapt to changing priorities, so companies can stay in their program as needs grow and evolve. This flexibility is crucial, as companies often need to pivot between different types of research and adapt their facilities to meet new scientific demands. Traditional labs, built for specific types of research, lack this adaptability, typically require extensive modifications and incur high costs to accommodate changes.
The need for speed in modern biotech research is key to ensure a drugs success in the market. With a high failure rate in drug development, companies need to maximize their chances of success. They can do this by optimizing costs, improving operational efficiencies and decreasing unnecessary delays. SmartLabs meets this need by offering lab environments, including R&D research spaces, in vivo suites and CleanSuites that can be available and ready for use in just two to four weeks. In addition to this rapid deployment, SmartLabs provides industry expertise to help their member companies navigate the complexities of research and infrastructure needs. This model provides operational support services, driven by SmartLabs’ team of industry experts, that enable their member companies to focus on the research.
SmartLabs also offers a flexible, fee-based model, contrasting with traditional lab spaces that require large upfront investments. These short-term, variable-cost structures are more aligned with the financial realities of today’s life sciences climate, helping companies manage capital more effectively and avoid the burdens of fixed costs.
As drug development shifts from a one-size-fits-all model to a more personalized approach, SmartLabs provides modern solutions that support the industry’s evolving needs. Their fast-to-start, flexible, and cost-effective lab environments help innovators focus on scientific breakthroughs instead of managing the complexities of lab setup and operations. SmartLabs aims to remove operational barriers, allowing their member companies to concentrate on research and development efforts.
You May Also Like
